Pathogenesis and Management of Non-Insulin-Dependent Diabetes Mellitus

  • William C. Duckworth

Abstract

The pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM) remains uncertain. Although over the past few years many of the abnormalities present in the disease have been identified, the mechanism or mechanisms by which these develop have not been established (Table 4.1). The two major abnormalities that are present in essentially all patients with overt NIDDM are insulin resistance and defective insulin secretion.1 Which of these is primary remains an area of considerable controversy. Since both are essentially present in all patients with NIDDM, the assumption may be that both are required for the clinical expression of this disease. In populations in which there is a high occurrence of NIDDM, such as the Pima Indians or South Pacific islanders, insulin resistance can be detected prior to the development of overt glucose intolerance or prior to detectable abnormalities in insulin secretion.2 This suggests that in these groups, insulin resistance might be the primary abnormality, and in susceptible individuals this could ultimately result in abnormalities in insulin secretion and the full development of NIDDM.

Keywords

Cholesterol Sugar Obesity Carbohydrate Osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeFronzo RA. The triumvirate: B-cell, muscle, liver: A collusion responsible for NIDDM. Lilly Lecture, 1987. Diabetes 1988;37(6):667–687.PubMedCrossRefGoogle Scholar
  2. 2.
    Stern MP. Type II diabetes mellitus: Interface between clinical and epidemiological investigation. Diabetes Care 1988;11(2):119–126.PubMedCrossRefGoogle Scholar
  3. 3.
    Efendic S, Hanson U, Persson B, Wajngot A, Luft R. Glucose tolerance, insulin release, and insulin sensitivity in normal-weight women with previous gestational diabetes mellitus. Diabetes 1987;36:413–419.PubMedCrossRefGoogle Scholar
  4. 4.
    Hinsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119.Google Scholar
  5. 5.
    Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Reaven GM. Insulin resistance in noninsulin-dependent diabetes mellitus: Does it exist and can it be measured? Am J Med 1983;74:3.PubMedCrossRefGoogle Scholar
  7. 7.
    Lillioja MB, et al. Impaired glucose tolerance as a disorder of insulin action: Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318(19):1217–1225.Google Scholar
  8. 8.
    Yki-Jarvinen H, et al. Dissociation of in vitro sensitivities of glucose transport and antilipolysis to insulin in NIDDM. Am J Physiol 1987;253 (Endocrinol Metab 16):E300-E304.PubMedGoogle Scholar
  9. 9.
    Ward WK, Beard JC, Porte D Jr. Clinical aspects of islet B-Cell function in noninsulin-dependent diabetes mellitus. Diabetes/Metab Rev 1986;2(3,4):297–313.CrossRefGoogle Scholar
  10. 10.
    Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S. Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 1981;30:590–595.PubMedCrossRefGoogle Scholar
  11. 11.
    Duckworth WC, Kitabchi AW. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 1972;53:418–427.PubMedCrossRefGoogle Scholar
  12. 12.
    Ward WK, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698–702.PubMedCrossRefGoogle Scholar
  13. 13.
    Duckworth WC, Kitabchi AW. The effect of age on plasma proinsulin in response to oral glucose. J Lab Clin Med 1976;88:359–367.PubMedGoogle Scholar
  14. 14.
    Polonsky KS, et al. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. N Engl J Med 318(19):1231–1239.Google Scholar
  15. 15.
    O’Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin dependent diabetes. N Engl J Med 318(19):1225–1230.Google Scholar
  16. 16.
    Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988;250:625–640.PubMedGoogle Scholar
  17. 17.
    Firth RG, et al. Post-prandial hyperglycemia in patients with non-insulin dependent diabetes mellitus: Role of hepatic and extrahepatic tissues. J Clin Invest 77:1525–1532.Google Scholar
  18. 18.
    Golay A, Swislocki ALM, Chen Y-DI, Reaven GM. Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 1987;36:692–696.PubMedCrossRefGoogle Scholar
  19. 19.
    Reaven GM, Chang H, Hoffman BB. Additive hypoglycemic effects of drugs that modify free fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes 1988;37(1):28–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Streja D, Boyko E, Rabkin SW Nutrition therapy in non-insulin-dependent diabetes mellitus. Diabetes Care 1981;4:81–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Vinik AI, Jenkins DJA. Dietary fiber in management of diabetes. Diabetes Care 1988;11(2):160–173.PubMedCrossRefGoogle Scholar
  22. 22.
    American Diabetes Association. Position statement: Nutritional recommendations and principles for individuals with diabetes mellitus: 1986. Diabetes Care 1987;10:126–132.Google Scholar
  23. 23.
    Horton ES. Role and management of exercise in diabetes mellitus. Diabetes Care 1988;11(2):201–211.PubMedCrossRefGoogle Scholar
  24. 24.
    Groop L, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetes. Eur J Clin Pharmacol 1985;28:697–704.PubMedCrossRefGoogle Scholar
  25. 25.
    Duckworth WC, Solomon SS, Kitabchi AE. Effects of chronic sulfonylurea therapy on plasma proinsulin levels. J Clin Endocrinol Metab 1972;35:585–591.PubMedCrossRefGoogle Scholar
  26. 26.
    Stolar MW. Athersclerosis in diabetes: The role of hyperinsulinemia. Metab Clin Exp 1988;37(2) Suppl 1:1–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Modan M, et al. Hyperinsulinemia—a link between glucose intolerance, obesity, hypertension, dyslipoproteinemia, elevated serum uric acid, and internal cation imbalance. Diabete Metab (Paris) 1987;13:375–380.Google Scholar
  28. 28.
    Fournier AM, et al. Blood pressure, insulin, and glycemia in nondiabetic subjects. Am J Med 1986;80:861–864.PubMedCrossRefGoogle Scholar
  29. 29.
    Falholt K, Cutfield R, Alejandro R, Heding L, Mintz D. The effects of hyperinsulinemia of arterial wall and peripheral muscle metabolism in dogs. Metabolism 1985;34(12):1146–1149.PubMedCrossRefGoogle Scholar
  30. 30.
    Torbay N, et al. Insulin increases body fat despite control of food intake and physical activity. Am J Physiol 1985;248 (Regul Integrative Comp Physiol 17):R120-R124.PubMedGoogle Scholar
  31. 31.
    DCCT Research Group: Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988;11(7):567–573.CrossRefGoogle Scholar
  32. 32.
    Harris MD, Davidson MB, Bush MA. Exogenous insulin therapy slows weight loss in type 2 diabetic patients. Int J Obesity 1988;12:149–155.Google Scholar
  33. 33.
    Longnecker MP, et al. Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch Intern Med 1986;146:673–676.PubMedCrossRefGoogle Scholar
  34. 34.
    Lardinois CK, Liu GC, Reaven GM. Glyburide in non-insulin-dependent diabetes: Its therapeutic effect in patients with disease poorly controlled by insulin alone. Arch Intern Med 145:1028–1032.Google Scholar
  35. 35.
    The Working Group on Hypertension in Diabetes Statement on Hypertension in Diabetes Mellitus. Arch Int Med 1987;147:830–842.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York  1990

Authors and Affiliations

  • William C. Duckworth

There are no affiliations available

Personalised recommendations